- Home
- ALNY vs XEL Comparison
ALNY vs XEL Comparison
Compare ALNY & XEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- XEL
- Stock Information
- Founded
- ALNY 2002
- XEL 1909
- Country
- ALNY United States
- XEL United States
- Employees
- ALNY N/A
- XEL N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- XEL Power Generation
- Sector
- ALNY Health Care
- XEL Utilities
- Exchange
- ALNY Nasdaq
- XEL Nasdaq
- Market Cap
- ALNY 33.2B
- XEL 39.2B
- IPO Year
- ALNY 2004
- XEL N/A
- Fundamental
- Price
- ALNY $264.99
- XEL $67.68
- Analyst Decision
- ALNY Buy
- XEL Buy
- Analyst Count
- ALNY 24
- XEL 13
- Target Price
- ALNY $299.09
- XEL $69.00
- AVG Volume (30 Days)
- ALNY 643.5K
- XEL 3.5M
- Earning Date
- ALNY 02-13-2025
- XEL 02-06-2025
- Dividend Yield
- ALNY N/A
- XEL 3.23%
- EPS Growth
- ALNY N/A
- XEL 6.51
- EPS
- ALNY N/A
- XEL 3.37
- Revenue
- ALNY $2,094,795,000.00
- XEL $13,763,000,000.00
- Revenue This Year
- ALNY $24.87
- XEL $3.74
- Revenue Next Year
- ALNY $18.53
- XEL $6.96
- P/E Ratio
- ALNY N/A
- XEL $20.10
- Revenue Growth
- ALNY 21.54
- XEL N/A
- 52 Week Low
- ALNY $141.98
- XEL $46.79
- 52 Week High
- ALNY $304.39
- XEL $73.38
- Technical
- Relative Strength Index (RSI)
- ALNY 61.89
- XEL 54.99
- Support Level
- ALNY $245.69
- XEL $64.61
- Resistance Level
- ALNY $256.93
- XEL $66.52
- Average True Range (ATR)
- ALNY 9.38
- XEL 1.33
- MACD
- ALNY 2.95
- XEL 0.19
- Stochastic Oscillator
- ALNY 99.91
- XEL 91.73
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About XEL Xcel Energy Inc.
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US with more than half of its electricity sales coming from carbon-free energy.